Freenome has partnered with Abbott to commercialize the test, which is expected to be available in the US this fall. The Food and Drug Administration (FDA) has approved Freenome’s SimpleScreen ™ CRC, ...

New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...

Please provide your email address to receive an email when new articles are posted on . Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially ...

Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal cancer screening options, giving healthcare providers more ways to help ...

US regulators may soon clear blood-based biomarker tests for colorectal cancer (CRC), expanding potential options for patients seeking more convenient forms of screening. Most recently, Guardant ...

Please provide your email address to receive an email when new articles are posted on . CMS will use newly defined criteria to qualify noninvasive biomarker CRC screening tests for coverage. Concerns ...

Colorectal cancer screening preferences differ across underserved populations, suggesting that aligning screening options with patient preferences may help improve screening uptake and adherence. A ...

Results of multi-institutional clinical study published in peer reviewed journal ‘Cancers’ confirms efficacy of Oxford BioDynamics’ EpiSwitch® blood-based Colorectal No-Stool Test (NST) High accuracy ...